On-farm milk cooling solution based on insulated cans with integrated ice compartment

Schubmehl and Sussman thank Drs. Butala and Pontone for their response and would like to clarify and expand upon several points that the authors brought to our attention. Our commentary did not intend to raise ethical concerns related to the development of the Scale for the Assessment of Positive Sy...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of geriatric psychiatry 2018-10, Vol.26 (10), p.1014
Main Authors: Torres-Toledo, Victor, Hack, Alice, Mrabet, Farah, Salvatierra-Rojas, Ana, Müller, Joachim
Format: Article
Language:eng ; fre
Subjects:
Clinical trials
FDA approval
Medical treatment
Parkinson's disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Schubmehl and Sussman thank Drs. Butala and Pontone for their response and would like to clarify and expand upon several points that the authors brought to our attention. Our commentary did not intend to raise ethical concerns related to the development of the Scale for the Assessment of Positive Symptoms-Parkinson's disease or the phase 3 trial. Nonetheless, they felt it was important to draw attention to the industry affiliations of various authors for two reasons: First, there is strong evidence that research conducted by authors with financial relationships with pharmaceutical companies is more likely to result in proindustry conclusions, and for this reason such research should be interpreted with an awareness of the potential for bias. Here, Schubmehl and Sussman demonstrate the efficacy of pimavanserin.
ISSN:1064-7481
1545-7214